Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- SARS (3) (remove)
Institute
- Medizin (2)
- Gesellschaftswissenschaften (1)
“Aber bitte mit Sicherheit!” – und nicht mehr mit Sahne – müsste Udo Jürgens heutzutage eigentlich singen, denn das Etikett Sicherheit wird gerade im Globalisierungszeitalter sehr schnell auf viele low politics-Themen gepackt. Deren potenzielle Problemlösung, so die nachfolgende Argumentation, könnte ohne das high politics-Upgrade – also die Bedeutungsverschiebung in die Nähe des Bereichs militärischer, das staatliche Überleben gefährdender Bedrohungen –, vielleicht effektiver und/oder legitimer von statten gehen.
Die aktuelle National Security Strategy der USA ist dafür ein vitales Beispiel, indem sie z. B. Gesundheitsbedrohungen ganz offiziell einen substanziellen Sicherheitsstatus zuweist: “Pandemic disease[s] threaten the security of regions and the health and safety of the American people”. [Quelle] Warum aber mit dem Sicherheitsupgrade nicht alles besser wird, kann man gut im Bereich der internationalen Pandemieprävention zeigen. Der Beitrag versteht sich als ein normatives Plädoyer gegen zu viel Sicherheit und möchte mit den folgenden zwei Punkten zum Nachdenken anregen...
Severe acute respiratory syndrome (SARS) is a new infectious disease caused by a novel coronavirus that leads to deleterious pulmonary pathological features. Due to its high morbidity and mortality and widespread occurrence, SARS has evolved as an important respiratory disease which may be encountered everywhere in the world. The virus was identified as the causative agent of SARS due to the efforts of a WHO-led laboratory network. The potential mutability of the SARS-CoV genome may lead to new SARS outbreaks and several regions of the viral genomes open reading frames have been identified which may contribute to the severe virulence of the virus. With regard to the pathogenesis of SARS, several mechanisms involving both direct effects on target cells and indirect effects via the immune system may exist. Vaccination would offer the most attractive approach to prevent new epidemics of SARS, but the development of vaccines is difficult due to missing data on the role of immune system-virus interactions and the potential mutability of the virus. Even in a situation of no new infections, SARS remains a major health hazard, as new epidemics may arise. Therefore, further experimental and clinical research is required to control the disease.
Keywords: Severe Acute Respiratory Syndrome; SARS; coronavirus; molecular mechanisms; therapy; vaccination
Background: Experimental animal data show that protection against severe acute respiratory syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible. For an effective immune prophylaxis in humans, broad coverage of different strains of SARS-CoV and control of potential neutralization escape variants will be required. Combinations of virus-neutralizing, noncompeting mAbs may have these properties. Methods and Findings: Human mAb CR3014 has been shown to completely prevent lung pathology and abolish pharyngeal shedding of SARS-CoV in infected ferrets. We generated in vitro SARS-CoV variants escaping neutralization by CR3014, which all had a single P462L mutation in the glycoprotein spike (S) of the escape virus. In vitro experiments confirmed that binding of CR3014 to a recombinant S fragment (amino acid residues 318–510) harboring this mutation was abolished. We therefore screened an antibody-phage library derived from blood of a convalescent SARS patient for antibodies complementary to CR3014. A novel mAb, CR3022, was identified that neutralized CR3014 escape viruses, did not compete with CR3014 for binding to recombinant S1 fragments, and bound to S1 fragments derived from the civet cat SARS-CoV-like strain SZ3. No escape variants could be generated with CR3022. The mixture of both mAbs showed neutralization of SARS-CoV in a synergistic fashion by recognizing different epitopes on the receptor-binding domain. Dose reduction indices of 4.5 and 20.5 were observed for CR3014 and CR3022, respectively, at 100% neutralization. Because enhancement of SARS-CoV infection by subneutralizing antibody concentrations is of concern, we show here that anti-SARS-CoV antibodies do not convert the abortive infection of primary human macrophages by SARS-CoV into a productive one. Conclusions: The combination of two noncompeting human mAbs CR3014 and CR3022 potentially controls immune escape and extends the breadth of protection. At the same time, synergy between CR3014 and CR3022 may allow for a lower total antibody dose to be administered for passive immune prophylaxis of SARS-CoV infection.